MAP3K4 is critical for the resistance to BRAF inhibitor in melanoma

被引：0
|
作者：
Hong, J. [1 ,2 ]
Lee, T. [3 ]
Wee, W. [3 ]
Chen, Y. [4 ]
机构：
[1] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Dept Dermatol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
[4] Natl Taiwan Univ, Grad Inst Med Genom & Prote, Taipei, Taiwan
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2018年 / 138卷 / 05期
关键词：
D O I：
10.1016/j.jid.2018.03.1233
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1218
引用
收藏
页码：S207 / S207
页数：1
相关论文
共 50 条
  • [31] Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma
    Nickoloff, Brian J.
    Vande Woude, George
    PIGMENT CELL & MELANOMA RESEARCH, 2012, 25 (06) : 758 - 761
  • [32] Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
    Vergani, Elisabetta
    Beretta, Giovanni L.
    Aloisi, Mariachiara
    Costantino, Matteo
    Corno, Cristina
    Frigerio, Simona
    Tinelli, Stella
    Dugo, Matteo
    Accattatis, Felice Maria
    Granata, Agnese
    Arnaboldi, Lorenzo
    Rodolfo, Monica
    Perego, Paola
    Gatti, Laura
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [33] Piperlongumine, a novel treatment option to overcome BRAF inhibitor resistance in melanoma
    Ramachandran, Sharavan
    Fofaria, Neel
    Srivastava, Sanjay
    CANCER RESEARCH, 2018, 78 (13)
  • [34] New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma
    Pinto, Rosamaria
    De Summa, Simona
    Garrisi, Vito Michele
    Strippoli, Sabino
    Azzariti, Amalia
    Guida, Gabriella
    Guida, Michele
    Tommasi, Stefania
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [35] Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
    Amanda Lassen
    Mohammad Atefi
    Lidia Robert
    Deborah JL Wong
    Michael Cerniglia
    Begonya Comin-Anduix
    Antoni Ribas
    Molecular Cancer, 13
  • [36] P63 contributes to acquired BRAF inhibitor resistance in melanoma
    Patel, A.
    Harwood, C.
    Bergamaschi, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (05) : E52 - E52
  • [37] BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma
    Li, Ying-Ying
    Wu, Chunjing
    Chen, Shu-Mei
    Wangpaichitr, Medhi
    You, Min
    Spector, Seth
    Feun, Lynn G.
    Kuo, Macus T.
    Savaraj, Niramol
    CANCER RESEARCH, 2014, 74 (19)
  • [38] BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
    Rizos, Helen
    Menzies, Alexander M.
    Pupo, Gulietta M.
    Carlino, Matteo S.
    Fung, Carina
    Hyman, Jessica
    Haydu, Lauren E.
    Mijatov, Branka
    Becker, Therese M.
    Boyd, Suzanah C.
    Howle, Julie
    Saw, Robyn
    Thompson, John F.
    Kefford, Richard F.
    Scolyer, Richard A.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1965 - 1977
  • [39] Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
    Chan, Xian Yang
    Singh, Alamdeep
    Osman, Narin
    Piva, Terrence J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [40] Modeling BRAF inhibitor resistance in genetically engineered mouse models of melanoma
    Kwong, Lawrence N.
    Jiang, Shan
    Chin, Lynda
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
12345